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Abstract
Cyclic AMP- (cAMP) and calcium-dependent agonists stimulate chloride secretion through the
coordinated activation of distinct apical and basolateral membrane channels and ion transporters in
mucosal epithelial cells. Defects in the regulation of Cl– transport across mucosal surfaces occur
with cystic fibrosis and V. cholerae infection and can be life threatening. Here we report that
secramine B, a small molecule that inhibits activation of the Rho GTPase Cdc42, reduced cAMP-
stimulated chloride secretion in the human intestinal cell line T84. Secramine B interfered with a
cAMP-gated and Ba2+-sensitive K+ channel, presumably KCNQ1/KCNE3. This channel is
required to maintain the membrane potential that sustains chloride secretion. In contrast,
secramine B did not affect the Ca2+-mediated chloride secretion pathway, which requires a
separate K+ channel activity from that of cAMP. Pirl1, another small molecule structurally
unrelated to secramine B that also inhibits Cdc42 activation in vitro, similarly inhibited cAMP-
dependent but not Ca2+-dependent chloride secretion. These results suggest that Rho GTPases
may be involved in the regulation of the chloride secretory response and identify secramine B an
inhibitor of cAMP-dependent K+ conductance in intestinal epithelial cells.
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1. Introduction
Transepithelial chloride secretion drives water transport across epithelial barriers for the
hydration of all mucosal surfaces. It requires the coordinated activity of membrane
transporters and channels differentially distributed on the lumenal (apical) and serosal
(basolateral) plasma membranes [1]. Chloride ions enter intestinal epithelial cells from the
basolateral surface together with sodium and potassium by passing through the basolateral
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Na+, K+, 2Cl– cotransporter (NKCC) following the inwardly directed Na+ electrochemical
gradient established by the basolateral Na+, K+ ATPase. Chloride then exits the opposite
apical cell surface by passing through the cAMP-activated cystic fibrosis transmembrane
conductance regulator (CFTR) or the Ca2+-activated chloride channel (CaCC). Export of K+
across the basolateral membrane maintains the electrochemical potential required to sustain
apical Cl– secretion. In the intestine, this is likely accomplished by the KCNQ1/KCNE3 and
the KCNN4 channels, gated open by intracellular cAMP or Ca2+, respectively [2,3].
Although the general features of cAMP and Ca2+-induced chloride secretion are understood,
such as the channels required to sustain chloride secretion, little is known about the
coordinated activation and regulation of these chloride secretion pathways.
Several years ago, we synthesized a collection of ~2500 small molecules and screened it for
inhibition of membrane traffic from the endoplasmic reticulum (ER) to the plasma
membrane via the Golgi apparatus [4]. We identified the structurally related compounds
secramine A and secramine B as inhibitors of protein export from the Golgi apparatus to the
plasma membrane and subsequently found that they inhibit association of the small Rho
GTPase Cdc42 with membranes [5]. Rho GTPases cycle between an inactive, GDP-bound
conformation, and an active, GTP-bound conformation. They are best known for regulating
actin cytoskeleton dynamics [6], but they also participate in membrane traffic, cell–cell
contact, cell-cycle progression, and cell polarity [7].
To investigate whether secramines also inhibit membrane traffic in the reverse direction,
namely from the Golgi to the ER, we next studied the effect of secramine B on cholera
toxin-induced Cl– secretion. Cholera toxin is the major pathogenic factor causing disease in
V. cholerae infection. The toxin is an enzyme that acts by entering the cytoplasm of host
cells to activate adenylyl cyclase, which converts ATP to cAMP and thereby stimulates Cl–
secretion. To access the cytoplasm, cholera toxin binds to receptors on the plasma
membrane and traffics to the trans-Golgi network and then to ER [30], where the
enzymatically active portion, the A1 chain, unfolds and passes into the cytoplasm by co-
opting the endogenous ER retro-translocation machinery [8]. The A1 chain subsequently
refolds in the cytoplasm and activates adenylyl cyclase by catalyzing the ADP-ribosylation
of the regulatory heterotrimeric G-protein Gsα.
We found that secramine B inhibited Cl– secretion induced by cholera toxin. Secramine B,
however, did not appear to act by inhibiting retrograde transport from the Golgi to the ER.
Rather it acted downstream of cholera toxin-induced cAMP production by inhibiting K+
efflux through a basolateral K+ channel, likely KCNQ1/KCNE3. In support of this
observation, we found that pirl1, a small molecule structurally unrelated to secramine B that
also inhibits Rho GTPase function in vitro, also prevented Cl– secretion in T84 cells induced
by cAMP agonists [9]. Neither secramine B nor pirl1, however, inhibited Cl– secretion
induced by Ca2+-dependent agonists. Thus, these results suggest a novel regulatory role for
Rho GTPases in gating KCNQ1/KCNE3 K+ channels and modulating the extent of intestinal
Cl– secretion induced by cAMP-agonists.
2. Materials and Methods
2.1. Reagents
Secramine B was synthesized as previously described [5] and stored in 20 mM aliquots in
DMSO at –20 °C. Cholera toxin (EMD Biosciences Inc., San Diego, CA), forskolin (Sigma–
Aldrich, St. Louis, MO), 8-Br cAMP (Sigma–Aldrich), BaCl2 (Fisher Scientific Co.,
Hanover Park, IL), amphotericin B (Sigma–Aldrich) were used. Jeffrey Peterson (Fox Chase
Cancer Center, Philadelphia, PA) kindly provided pirl1 and its negative control pirl1.6. T84
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cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and
cultured as described [10].
2.2. Electrophysiology assays
Cl– secretion, assessed as short circuit current (Isc), and transepithelial resistance were
measured using standard electrophysiological techniques with T84 cell monolayers grown
on 0.33 cm2 inserts [10]. Vehicle represents the addition of 0.25% BSA and 0.2% DMSO to
the basolateral media. Secramine B, pirl1 and pirl1.6 were only added to the basolateral
media and concentrations are reported as the total volume around the cell monolayers (200
μL apical media + 1000 μL basolateral media). A higher percentage of DMSO (above
0.5%) reduces the transepithelial resistance and BSA serves as a carrier for secramine B
(data not shown). Where used, forskolin, carbachol, 8Br-cAMP, and barium chloride were
added to the basolateral media and cholera toxin was added to the apical media. Data were
fitted to a variable slope sigmoidal dose response curve and plotted using GraphPad Prism
3.0.
2.3. Short-circuit current measurement in semi-permeabilized monolayers
T84 cell monolayers were incubated with secramine B or vehicle in buffers containing K+ or
Cl– as the sole permeant ions. Basolateral membrane K+ conductances (Isc-blK) were
determined in cells permeabilized apically with 20 μM amphotericin B, in the presence of
asymmetrical buffers that imposed a basolaterally directed seven-fold K+ gradient (apical
solution: 140 mM KGluconate, 1.25 mM CaSO4, 0.4 mM MgSO4, 10 mM HEPES, 5.6 mM
D-glucose, pH 7.4; basal solution 20 mM KGluconate, 1.25 mM CaSO4, 0.4 mM MgSO4,
120 mM NMDG, 10 mM HEPES, 5.6 mM D-glucose, pH 7.4) [11]. Transmembrane
potential was clamped at 0 mV, and (Isc-blK) was measured before and after 10 mM
forskolin or 100 μM carbachol addition to the basolateral media. Apical Cl– conductances
(Isc-apCl) were determined in cells permeabilized basolaterally using 100 μM amphotericin
B, in the presence of symmetric high Cl– buffer (0.7 mM NaPO4, 0.43 mM KPO4, 1.25 mM
CaCl2, 0.4 mM MgSO4, 142.3 mM choline, 10 mM HEPES, 5.6 mM D-glucose, pH 7.4)
with transmembrane potential clamped at +10 mV (apical) [12]. For (Isc-blK), transepithelial
current–voltage relationships (I–V curves) were defined by measuring transepithelial
currents during 1 s voltage clamp periods ranging from 80 to +80 mV and normalized to
baseline Isc at rest as described [12]. Baseline I–V curves obtained in the absence of agonist
were subtracted from those measured after agonist treatment to calculate agonist-induced
currents.
3. Results
3.1. Secramine B inhibits cAMP-induced Cl– secretion from intestinal cells
T84 cells reproduce the cAMP- and Ca2+-regulated Cl– secretion observed in native
intestinal tissue [13] and increase Cl– secretion in response to cholera toxin, a cAMP
agonist. We tested whether secramine B (Fig. 1A) inhibited the cholera toxin-induced
increase in Cl– secretion in these cells. Secramine B, as opposed to secramine A, was
selected for evaluation because it is more soluble than secramine A and could be used at low
vehicle (DMSO) doses that did not perturb transepithelial resistances in polarized T84
epithelial cells.
Secramine B (25 μM) strongly inhibited cholera toxin-induced Cl– secretion (Isc) (Fig. 1B)
and had no effect on transepithelial resistance (TER) over a 5 h incubation period, indicating
that intercellular tight junctions were not affected and the monolayers remained intact (TER
= 1080 and 1180 Ω cm2 with 25 μM secramine B and vehicle, respectively, at 5 h).
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To distinguish whether secramine B inhibited the retrograde traffic of cholera toxin from the
Golgi to the ER, or the signaling pathway leading to Cl– secretion, we applied forskolin, a
direct activator of adenylyl cyclase, to increase the intracellular levels of cAMP or 8Br-
cAMP, a membrane-permeable analog of cAMP. Secramine B inhibited Cl– secretion by
>90% in the presence of 10 μM forskolin (Fig. 2A) or 3 mM 8Br-cAMP (Fig. 2B).
Secramine B acted with an IC50 of ~3.4 μM (Fig. 2C). When added after the forskolin-
induced Isc was maximal, secramine B still potently inhibited Cl– secretion with a half-time
of approximately 17 min (Fig. 2D). Thus, the entire inhibitory effect of secramine B on the
cholera toxin-induced increase in Cl– secretion can be explained by inhibition of a step(s)
downstream of retrograde traffic from Golgi to ER and cAMP production.
3.2. Secramine inhibits the basolateral cAMP-gated K+ efflux
Four distinct membrane events are responsible for the cAMP-elicited vectorial transport of
Cl– : (1) increase in the basolateral Na+ efflux by the Na+, K+ ATPase pump; (2) basolateral
electroneutral influx of Cl– through the bumetanide-sensitive NKCC transporter; (3) apical
passive diffusion of Cl– through the CFTR channel; and (4) increase in the basolateral efflux
of K+ through Ba2+-sensitive channels [1]. Both the NKCC transporter and the Na+, K+
ATPase are required for cAMP- and Ca2+-elicited Cl– secretion [14,15]. Therefore, we
tested whether secramine might also inhibit Cl– secretion caused by the muscarinic agonist
carbachol that acts by inducing an increase in intracellular Ca2+. Secramine B had no
detectable effect on the Isc induced by carbachol (Fig. 3). Based on these observations, we
reasoned that secramine B inhibited either the apical CFTR or the cAMP-gated basolateral
K+ channel.
To test whether secramine B inhibited the CFTR channel, we monitored Cl– flux across the
apical membranes of T84 monolayers in response to forskolin in the presence of
amphotericin B, a polyene that forms channels for monovalent ions and small molecules.
Under these conditions, the forskolin-induced transepithelial Isc is only due to Cl– transport
across the apical membrane. Confluent monolayers of T84 cells were placed in symmetrical
solutions containing only Cl– as the major charge carrying permeant ion. We then
selectively permeabilized the basolateral membranes with amphotericin B, and clamped the
apical membrane potential at 10 mV [11]. Under these conditions, secramine B had no effect
on the Cl– flux stimulated upon addition of 10 μM forskolin (Isc-apCl, Fig. 4A), suggesting
that secramine B does not inhibit the cAMP-sensitive CFTR channel.
To test if secramine B affected cAMP-regulated basolateral K+ efflux, we again used
amphotericin B, but instead applied it to the apical membrane of T84 cells. We immersed
confluent monolayers of T84 cells in asymmetrical solutions containing K+ as the major
charge carrying permeant ion, permeabilized the apical membranes with amphotericin B,
and clamped the transepithelial voltage at 0 mV [11]. The apical solution had a seven-fold
higher concentration of K+. Forskolin (10 μM) induced a strong K+ current across the
basolateral membrane (Isc-blK) that was inhibited by 20 μM secramine B (Fig. 4B).
Subsequent addition of 3 mM BaCl2 rapidly and strongly inhibited the cAMP-gated K+
channel activity [16]. Barium does not inhibit carbachol-stimulated K+ channel activity [17].
Upon addition of carbachol, we observed transient and strong basolateral K+ efflux in both
secramine-treated and untreated monolayers, indicating that secramine B-treated monolayers
were still intact and transport-competent and that secramine B had no effect on Ca2+-gated
K+ channel activity. Steady-state Isc-blK/V relationships after stimulation of T84
monolayers with forskolin also demonstrated that secramine B inhibited cAMP-induced K+
conductance as evidenced by the lower slope of the current–voltage isotherm (Fig. 4C).
These results show that secramine B selectively attenuated K+ efflux through a cAMP-
regulated and Ba2+-sensitive basolateral K+ efflux pathway, presumably via the K+ channel
KCNQ1/KCNE3 [2].
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3.3. Rho GTPase activity and cAMP-dependent Cl– secretion
We have shown that secramine B inhibits the Rho GTPase Cdc42 in vitro, and proposed that
secramine B also targets Cdc42 in cells because it phenocopies perturbations in membrane
traffic resulting from expression of Cdc42 mutants [5]. Pirl1 is a small molecule structurally
unrelated to secramine B (Fig. 5A) that also inhibits Cdc42 in vitro in a manner similar to
secramine B [9]. Incubation of T84 cells with pirl1, but not its inactive analog pirl1.6 (Fig.
5B, [9]), inhibited forskolin-induced Cl– flux (Fig. 5B–D, IC50 of ~28 μM) and did not
inhibit carbachol-induced Cl– flux (Fig. 5D) or effect transepithelial resistance (data not
shown). Therefore, two structurally distinct Rho GTPase inhibitors, secramine B and pirl1,
both inhibited Cl– secretion induced by cAMP, strongly suggesting that Cl– transport is
indeed regulated by Rho GTPases.
4. Discussion
Here we provide evidence that secramine B and pirl1, two structurally distinct small
molecules that inhibit activation and signaling by the Rho GTPase Cdc42, prevented cAMP-
induced, but not Ca2+-induced, Cl– transport in polarized T84 epithelial cells. Secramine B
acted by inhibiting a basolateral cAMP-dependent K+ channel, likely comprised of the
voltage-gated KCNQ1 and its modulatory KCNE3 subunits [2]. This channel, but not the
related KCNE1, is expressed in the T84 cells and opens in response to cAMP agonists [2].
Neither the Ca2+-gated K+ channel KCNN4 nor the Cl– channel CFTR were affected by
secramine B. These results provide pharmacological evidence that Rho GTPases regulate
cAMP-dependent Cl– secretion and basolateral K+ efflux. Precisely how Rho GTPases
regulate these processes remains to be determined.
Rho GTPases likely regulate Cl– secretion downstream of cAMP production either through
alterations in the organization of the basolateral actin cytoskeleton or transport of channels,
channel components, or channel regulators to the basolateral membrane. Elevation of cAMP
causes a loss of basement stress fibers and an increase in actin bundles along the lateral
membranes of T84 cells [18]. Prevention of this actin redistribution by stabilizing the actin
stress fibers with NBD-phallicidin inhibits cAMP-induced Cl– secretion in T84 cells [18].
Both secramine B and pirl1 prevent Cdc42-dependent actin polymerization in cell extracts
and pirl1 inhibits PMA-induced actin rearrangements in monkey kidney epithelial BSC-1
cells [5,9]. Like secramine B and pirl1, NBD-phallicidin does not interfere with Ca2+-
mediated Cl– secretion induced by carbachol [18]. Among the Rho GTPases, RhoA
activation stimulates stress fiber formation and Cdc42 and Rac1 activation stimulate actin-
based structures along the cell periphery [6]. Therefore, the cytoskeletal rearrangements
downstream of cAMP production are consistent with an inhibition of RhoA and a
stimulation of Rac1 and Cdc42. In accordance with these expected changes, PKA, activated
upon increases in cAMP, directly phosphorylates RhoA to inhibit its function [19,20] and
indirectly activates Cdc42 [21], possibly through phosphorylation of guanine nucleotide
exchange factor for Cdc42 [22]. Importantly, although both the secramines and pirl1 inhibit
Cdc42 activation, neither inhibits activation of RhoA as monitored by stress fiber stability
[5,9]. Thus, the activities of secramine B and pirl1 are consistent with an inhibition of the
normal cytoskeletal changes that accompany elevations in cAMP and suggest that cAMP-
induced K+ channel activity may depend on these cytoskeletal changes.
Alternatively, cAMP-activated K+ channel activity may require Cdc42-dependent membrane
traffic. In polarized epithelial cells, overexpression of dominant inhibitory mutants of Cdc42
disrupts membrane traffic of newly synthesized proteins to the basolateral membrane [23–
25] and recycling of basolateral proteins to the basolateral membrane after endocytosis [23].
Therefore, by interfering with Cdc42 activity, secramine B and pirl1 may inhibit the
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mobilization of membrane-bound components of a fully functional cAMP-activated
basolateral K+ channel.
These studies do not rule out the possibility that secramine B and pirl1 inhibit cAMP-gated
K+ channel activity independent of an effect on Rho GTPases. Secramine B might bind
directly to and inhibit the cAMP-gated K+ conductance. Such a mechanism of inhibition by
direct binding to this channel was shown for chromanol 293B, a small molecule that, like
secramine B, also does not inhibit Ca2+-induced Cl– flux [26,27]. Furthermore, the KCNQ1
subunit is a promiscuous drug target, having been shown to bind to different small
molecules [28]. This possibility, however, seems unlikely since pirl1.6, a small molecule
that is highly similar to pirl1 but nevertheless does not inhibit Cdc42 activation, failed to
inhibit forskolin-stimulated Cl– transport.
Blockade of the cAMP-gated K+ conductance by secramine B resulted in strong inhibition
of the intestinal Cl– secretory response. In addition to identifying a new reagent to dissect
critically important K+ channels [29], this study pharmacologically links Rho GTPases to
Cl– secretion and thus provides a new avenue to dissect and elucidate the pathway of cAMP-
elicited Cl– secretion in intestinal crypt epithelial cells.
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CaCC calcium activated chloride channel
cAMP 3′,5′-cyclic AMP
CFTR cystic fibrosis transmembrane regulator
ER endoplasmic reticulum
Isc short circuit current
Isc-blK basolateral membrane potassium Isc
Isc-apCl apical membrane chloride Isc
I–V current–voltage
NKCC sodium potassium two chloride cotransporter
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Fig. 1.
Secramine B inhibits cholera toxin-induced Cl– secretion in T84 cell monolayers. (A)
Structure of secramine B. (B) Time course for Cl– secretion (Isc) in T84 monolayers induced
by the addition of cholera toxin to the apical media at the indicated time (dotted line) in the
presence of 25 μM secramine B (filled squares) or vehicle (0.2% DMSO, 0.25% BSA, open
squares) added at 0 min (mean ± S.D., n = 2).
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Fig. 2.
Secramine B inhibits cAMP-dependent Cl– secretion and acts downstream of cholera toxin
transport in T84 cell monolayers. T84 monolayers were incubated with vehicle (open
squares) or 20 μM secramine B (filled squares) for 45 min followed by the addition of 10
μM forskolin (A) or 3 mM 8Br-cAMP (B) to the basolateral media at 0 min and the Isc was
measured over time (mean ± S.D., n = 2). (C) Dose dependency of secramine B action on
Cl– secretory response elicited by 10 μM forskolin (mean ± S.D., n = 2). Secramine B has
an IC50 of ~3.4 μM. (D) T84 cells were incubated with 10 μM forskolin (0 min) followed
by 20 μM secramine B or vehicle at 15 min (dotted line) (mean ± S.D., n = 2).
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Fig. 3.
Secramine B does not inhibit Cl– secretion induced by carbachol. T84 cell monolayers were
treated with vehicle (open squares) or 20 μM secramine B (filled squares) for 45 min
followed by the addition of 100 μM carbachol to the basolateral media at 0 min (mean ±
S.D., n = 2).
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Fig. 4.
Secramine B selectively inhibits basolateral Ba2+-sensitive K+ conductance in T84 cell
monolayers. (A) T84 monolayers were exposed to a symmetrical high Cl– solution and
basolaterally permeabilized with 20 μM amphotericin B. At 0 min, 20 μM secramine B or
vehicle was added followed by 10 μM forskolin to the basolateral media (arrow). All
measurements for the secramine B-treated monolayer were shifted by 8 μA/cm2. Data is
representative of two independent experiments. (B) A basolaterally directed K+ gradient was
established across T84 monolayers and the apical membrane was permeabilized with 20 μM
amphotericin B. At 0 min, 20 μM secramine B or vehicle was added followed by 10 μM
forskolin, 3 mM BaCl2, and 100 μM carbachol to the basolateral media (arrows, as
indicated). Data is representative of four independent experiments. (C) A basolaterally
directed K+ gradient was established across T84 monolayers and the apical membrane was
permeabilized with 20 μM amphotericin B. Short circuit currents were recorded at the
indicated voltage-clamped test potentials. The ordinate indicates the current difference
measured on the same monolayer before and 10 min after 10 μM forskolin stimulation in the
presence of 20 μM secramine B or vehicle. Data is representative of two independent
experiments.
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Fig. 5.
Pirl1 selectively inhibits cAMP-dependent Cl– secretion in T84 cell monolayers. (A)
Structures of pirl1 and pirl1.6. (B) T84 monolayers were incubated with vehicle (open
squares), 20 μM pirl1 (filled squares), or pirl1.6 (filled circles) for 45 min followed by the
addition of 10 μM forskolin to the basolateral media at 0 min and the Isc was measured over
time (mean ± S.D., n = 2). (C) Dose dependency of pirl1 action on Cl– secretory response
elicited by 10 μM forskolin (mean ± S.D., n = 2). Pirl1 has an IC50 of ~28 μM. (D) Like
(B), with 50 μM pirl1 and the addition of 100 μM carbachol to the basolateral media at 20
min (mean ± S.D., n = 2).
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